Immunitybio Inc Total Liabilities
Immunitybio Inc total liabilities. Based on the latest financial reports, Immunitybio Inc (IBRX) has total liabilities worth $569.82 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Immunitybio Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Immunitybio Inc (2013–2024)
Total liabilities of Immunitybio Inc from 2013 to 2024. This chart illustrates how Immunitybio Inc's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Immunitybio Inc's assets to evaluate the company's liquid asset resilience ratio.
Immunitybio Inc Competitors by Total Liabilities
The table below lists competitors of Immunitybio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gates Industrial Corporation plc
NYSE:GTES
|
USA | $3.46 Billion |
|
Zhongtai Securities Co Ltd
SHG:600918
|
China | CN¥196.56 Billion |
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥1.05 Billion |
|
Home BancShares Inc
NYSE:HOMB
|
USA | $20.17 Billion |
|
Powertech Technology Inc
TW:6239
|
Taiwan | NT$51.89 Billion |
|
Australian Foundation Investment Company Ltd
AU:AFI
|
Australia | AU$1.59 Billion |
|
Tencent Music Entertainment Group
NYSE:TME
|
USA | $19.44 Billion |
|
Macronix International Co Ltd
TW:2337
|
Taiwan | NT$34.35 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Immunitybio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IBRX total asset value.
Liquidity & Leverage Metrics
Immunitybio Inc Total Liabilities Ratios Explained
Immunitybio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunitybio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunitybio Inc (2013–2024)
The table below shows the annual total liabilities of Immunitybio Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $871.06 Million | -20.11% |
| 2023-12-31 | $1.09 Billion | +34.26% |
| 2022-12-31 | $812.18 Million | +13.94% |
| 2021-12-31 | $712.82 Million | +109.73% |
| 2020-12-31 | $339.87 Million | +1414.31% |
| 2019-12-31 | $22.44 Million | -37.56% |
| 2018-12-31 | $35.94 Million | +13.76% |
| 2017-12-31 | $31.60 Million | +31.22% |
| 2016-12-31 | $24.08 Million | +121.84% |
| 2015-12-31 | $10.85 Million | +351.31% |
| 2014-12-31 | $2.40 Million | -51.88% |
| 2013-12-31 | $5.00 Million | -- |
About Immunitybio Inc
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therap… Read more